Jefferies Group restated their buy rating on shares of TherapeuticsMD Inc (NASDAQ:TXMD) in a research report sent to investors on Wednesday morning. They currently have a $18.00 price target on the stock.

Other equities analysts also recently issued reports about the stock. Guggenheim restated a buy rating on shares of TherapeuticsMD in a research note on Tuesday. Oppenheimer Holdings Inc. began coverage on shares of TherapeuticsMD in a research note on Tuesday, November 22nd. They issued an outperform rating and a $12.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a sell rating to a hold rating in a research note on Thursday, November 24th.

TherapeuticsMD (NASDAQ:TXMD) opened at 5.94 on Wednesday. The company’s market capitalization is $1.17 billion. The firm has a 50 day moving average of $6.27 and a 200-day moving average of $7.33. TherapeuticsMD has a 52 week low of $4.39 and a 52 week high of $11.26.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the propert of of Daily Political. If you are viewing this news story on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The original version of this news story can be read at http://www.dailypolitical.com/2016/12/01/therapeuticsmd-inc-txmd-receives-buy-rating-from-jefferies-group.html.

A number of large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of TherapeuticsMD by 8.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,465,462 shares of the company’s stock worth $159,800,000 after buying an additional 1,798,290 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the company’s stock worth $34,455,000 after buying an additional 426,991 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of TherapeuticsMD during the third quarter worth about $2,724,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of TherapeuticsMD by 8.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 4,005,977 shares of the company’s stock worth $27,281,000 after buying an additional 308,027 shares during the last quarter. Finally, Bamco Inc. NY increased its stake in shares of TherapeuticsMD by 105.2% in the third quarter. Bamco Inc. NY now owns 461,264 shares of the company’s stock worth $3,141,000 after buying an additional 236,468 shares during the last quarter.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.